JPMA Position Statements
JPMA is committed to contributing to the better health of patients worldwide through the promotion of drug discovery, research and development. In support of such research and to ensure that the resulting medicines safely reach the patients that need them, the JPMA has shared statements in the following areas:
Joint IFPMA-JPMA-PhRMA Letter for G20 Japan-Saudi transition:
Recommendations from Pharmaceutical Industry for G20 Health Ministers Meeting:
Recommendations from the pharmaceutical industry for the G20 Osaka Summit Health Agenda:
JPMA submitted "Recommendations from the pharmaceutical industry for the G20 Osaka Summit Health Agenda" to the Prime Minister of Japan, the Minister of Health, Labour and Welfare, the Minister of Finance and the Minister for Foreign Affairs.Please click below to learn more about JPMA’ recommendations.
JPMA's Activities for Access to Medicines in Developing Countries:
The United Nations High-Level Panel on Access to Medicines issued a report on September 14, 2016. JPMA recognizes that there are multi-layered challenges in addressing global access to medicines. It requires a solution with a holistic approach.Please to read more.
JPMA recommendations for G7 Health Minister's Meeting:
G7 Ise-Shima Summit:
Intellectual Property Rights:
We promote understanding of the important role of intellectual property rights in enabling drug discovery, research and development for new medicines while also creating access to such medicines. Please to learn more about JPMA' proposals.
Universal Health Coverage:
We are engaged in the ongoing discussion regarding the Post-2015 United Nations sustainable development goals and sees universal health coverage as a key contributor to the wealth and economic productivity of countries. Please to learn more about JPMA' proposals.